Want to see FR:ABNX full AI Analyst Report?
ABNX Stock Chart & Stats
€3.70
>-€0.01(-0.63%)
At close: 4:00 PM EST
€3.70
>-€0.01(-0.63%)
Day’s Range― - ―
52-Week Range€1.17 - €5.21
Previous CloseN/A
Volume9.43K
Average Volume (3M)284.77K
Market Cap
€88.06M
Enterprise Value€92.33M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding42,568,070
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic PlatformABIONYX’s concentrated R&D platform around apoA‑I creates a durable scientific specialization and potential platform effects across inflammatory and infectious indications. Deep domain focus can lower marginal R&D learning costs and enable reuse of preclinical/clinical insights across multiple programs over months to years.
Positive Equity BufferMaintaining positive equity provides a concrete solvency buffer and reduces immediate bankruptcy risk, giving management runway to advance clinical programs. While equity has weakened, this structural balance-sheet headroom supports continued operations and financing flexibility over the next several months if managed conservatively.
Reduced Operating Cash Burn TrendA reduction in operating cash outflows indicates management is achieving incremental efficiency or program rationalization. If this improvement persists, it meaningfully extends runway, lowers near‑term financing needs and improves the company’s ability to fund pivotal work without immediate dilutive capital raises.
Bears Say
Persistent Negative Cash FlowConsistent negative OCF and FCF are structural drains that require repeated financing or partner deals. Over a 2–6 month horizon this pressure raises dilution and refinancing risk, constrains ability to scale trials, and forces prioritization of programs rather than broad development—limiting strategic optionality.
Rising Leverage And Eroding EquityA near doubling of leverage and falling equity reduces financial flexibility and increases refinancing and covenant risk. This structural shift makes future capital raises more costly or dilutive, limiting the firm's ability to invest in clinical acceleration without accepting unfavorable terms or strategic compromises.
Weak And Deteriorating ProfitabilityMaterial margin deterioration and very large operating losses signal structural unprofitability that is not close to breakeven. Even with revenue gains, such negative operating leverage indicates a high funding burden to reach sustainable margins, threatening the durability of the business model absent significant clinical/ commercial inflection.
ABNX FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.17 and its highest was €5.21 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €88.06M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 80 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.091.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 42,568,070 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.455%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in FR:ABNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.